Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Findings from K. Bullock et al in breast cancer reported
July 17th, 2008
According to a study from the United States, "The taxanes docetaxel (Taxotere (R); Sanofi-Aventis U. S. LLC, Bridgewater, NJ) and paclitaxel ( Taxol (R); Bristol-Myers Squibb, Princeton, NJ) are highly active agents in metastatic breast cancer and may represent a safer alternative to anthracycline-based regimens when combined with the human epidermal growth factor receptor (HER)-2-targeted agent trastuzumab (Herceptin (R); Genentech Inc., South San Francisco, CA). A number of preclinical and early clinical studies have evaluated the feasibility, duration, and appropriate dosing schedule(s) for taxane-trastuzumab combinations in HER-2-positive metastatic breast cancer." ...
Source: Women's Health Weekly (2008-07-17)
|
